BeiGene, Ltd. logo
BeiGene, Ltd. BGNE

Annual report 2025
added 02-26-2026

report update icon

BeiGene, Ltd. Cash Flow 2011-2026 | BGNE

Annual Cash Flow BeiGene, Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

1.13 B -141 M -1.16 B -1.5 B -1.3 B -1.28 B -750 M -548 M 12.8 M -89.5 M -39.8 M - - - -

Depreciation & Amortization

142 M 172 M 87.7 M 66.3 M 46.5 M 31.8 M 18.6 M 10.4 M 4.76 M 1.91 M 1.54 M 1.56 M - - -

Accounts Payables

479 M 405 M 315 M 295 M 262 M 232 M 122 M 113 M 69.8 M 12 M - - - - -

Accounts Receivables

865 M 676 M 358 M 173 M 483 M 60.4 M 70.9 M 41.1 M 29.4 M - - - - - -

Total Inventories

608 M 495 M 416 M 282 M 243 M 89.3 M 28.6 M 16.2 M 10.9 M - - - - - -

All numbers in USD currency

Quarterly Cash Flow BeiGene, Ltd.

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - 44.1 M - - - -309 M - - - -564 M - -1.18 B -617 M -237 M - -791 M -295 M 125 M - -951 M -605 M -342 M - -483 M -218 M -172 M - -354 M -222 M -105 M - -81 M -87.6 M -35.7 M - -63.4 M -39.1 M - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

35.7 M 29.9 M 32.8 M - 70 M 23.8 M 25.3 M - 19.2 M 21.3 M 20 M - 15.2 M 14.5 M 16.6 M - 33.3 M 21.2 M 9.63 M - 24 M 15.6 M 7.75 M - 11.1 M 7.11 M 3.42 M - 7.02 M 4.58 M 2.24 M - 2.7 M 1.4 M 864 K - 1.44 M 492 K 439 K - 402 K 373 K 352 K - - - - - - - - - - - - - - - -

Accounts Payables

384 M 361 M 364 M 405 M 308 M 333 M 357 M 315 M 342 M 267 M 241 M 295 M 252 M 234 M 237 M 262 M 206 M 169 M 147 M 232 M 232 M 232 M 232 M 122 M 122 M 122 M 122 M 113 M 113 M 113 M 113 M 69.8 M 69.8 M 69.8 M 69.8 M 12 M 12 M 12 M 12 M 8.98 M 8.98 M 8.98 M 8.98 M - - - - - - - - - - - - - - - -

Accounts Receivables

863 M 771 M 717 M 676 M 569 M 529 M 435 M 358 M 309 M 299 M 310 M 173 M 189 M 172 M 191 M 483 M 130 M 73.8 M 84 M 60.4 M 60.4 M 60.4 M 60.4 M 70.9 M 70.9 M 70.9 M 70.9 M 41.1 M 41.1 M 41.1 M 41.1 M 29.4 M 29.4 M 29.4 M 29.4 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

532 M 503 M 495 M 495 M 432 M 443 M 447 M 416 M 317 M 321 M 297 M 282 M 291 M 262 M 246 M 243 M 151 M 118 M 73 M 89.3 M 89.3 M 89.3 M 89.3 M 28.6 M 28.6 M 28.6 M 28.6 M 16.2 M 16.2 M 16.2 M 16.2 M 10.9 M 10.9 M 10.9 M 10.9 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company BeiGene, Ltd., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
$ 3.44 2.99 % $ 303 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 218.06 -1.72 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Amgen Amgen
AMGN
$ 349.77 0.57 % $ 188 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.23 -1.38 % $ 899 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.6 0.76 % $ 6.06 B irlandaIrlanda
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Inventiva S.A. Inventiva S.A.
IVA
$ 6.08 5.19 % $ 138 M franceFrance
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.4 2.19 % $ 357 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.63 0.77 % $ 16.5 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 11.19 1.91 % $ 461 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.42 4.25 % $ 734 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.82 -4.08 % $ 3.29 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA